Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LW402 in Moderate-to-severe Atopic Dermatitis
NCT07370909Phase 3Recruiting
- Sponsor
- Shanghai Longwood Biopharmaceuticals Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lw402 in atopic dermatitis (AD) (3 arms), sponsored by Shanghai Longwood Biopharmaceuticals Co., Ltd. Primary endpoints: Eczema Area and Severity Index 75% improvement at 16 weeks and Investigator's Global Assessment score of 0 or 1 at 16 weeks. Started Mar 2026; status: recruiting.
02
Drugs
lw402
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07370909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07370909.